The
morbidity of pancreatic ductal
adenocarcinoma (PDAC) has been increasing over years, while the
treatment efficacy and
prognosis of PDAC remain far from satisfying. The newly-ermerged
tumor immunotherapy has not only made lots of breakthroughs in various
malignancies, but also brought an opportunity to the
treatment of
pancreatic cancer.PDAC
immunotherapies, mainly including
vaccine therapy, adoptive
T cell thanfer
therapy, checkpoint blockade
therapy, have achieved a certain effect, however, the clinical outcomes have not been satisfactory. Therefore, the combination of
immunotherapies based on different theoretical views is important and is likely to be the trend in the
future.
Carcinoma associated
fibroblast (CAF) is the most common
cell in
pancreatic cancer stromal component. It
will be helpful to develop more potential
therapeutic targets by further exploring CAF and the mechanism of
fibrosis mediated
immunosuppression.